Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 23,200 shares, a growth of 33.3% from the December 15th total of 17,400 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 63,600 shares, the days-to-cover ratio is presently 0.4 days.

Kamada Trading Up 1.0 %

Kamada stock opened at $7.16 on Friday. The firm has a 50 day simple moving average of $6.20 and a 200 day simple moving average of $5.76. Kamada has a 1-year low of $4.74 and a 1-year high of $8.00. The firm has a market capitalization of $411.56 million, a price-to-earnings ratio of 25.57 and a beta of 0.98.

Hedge Funds Weigh In On Kamada

An institutional investor recently bought a new position in Kamada stock. Plato Investment Management Ltd bought a new position in Kamada Ltd. (NASDAQ:KMDA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 21,785 shares of the biotechnology company’s stock, valued at approximately $117,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Kamada in a report on Friday, January 10th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.